In the 2020 ESGO-ESTRO-ESP guidelines, all POLE-mutated endometrial carcinomas up to FIGO stage II are included in the low-risk prognostic group, regardless of other clinicopathological features, such as tumor grade, histotype, LVSI, and depth of myometrial invasion. Here, POLE is linked to endometrial carcinoma.